Bicycle Therapeutics (BCYC) AI Stock Analysis

• Market Cap: $454.65M
• Dividend Yield: N/A
• Average Volume (3M): 341.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: -23.43%
• EPS Growth: -9.84%
• Country: US
• Employees: 305
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 49,929,950
• 10 Day Avg. Volume: 438,227
• 30 Day Avg. Volume: 341,904
• PEG Ratio: 0.11
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 23.10
• P/FCF Ratio: -4.91
• Enterprise Value/Market Cap: -0.23
• Enterprise Value/Revenue: -3.72
• Enterprise Value/Gross Profit: 0.63
• Enterprise Value/Ebitda: 0.39
• 1Y Price Target: $22.29
• Price Target Upside: 239.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -3.87
• Revenue Forecast (FY): $29.58M

• Rating: 41 Neutral
• Price Target: $6.00 ▼(-8.54% Downside)

Bicycle Therapeutics' overall stock score is primarily impacted by its challenging financial performance, characterized by declining revenues and persistent losses. Technical analysis indicates bearish momentum, and the valuation is unattractive due to the negative P/E ratio. The absence of earnings call insights and corporate events further limits positive influences on the score.

Positive Factors

Proprietary Technology

The proprietary Bicycle platform provides a competitive edge by offering innovative therapies, potentially leading to new treatment options and partnerships.

Low Leverage

Minimal leverage enhances financial stability, reducing risk and providing flexibility to invest in R&D and strategic initiatives.

Collaborative Revenue Model

Collaborations with larger pharmaceutical companies offer diversified revenue streams and potential for growth through milestone payments and royalties.

Negative Factors

Declining Revenue

Significant revenue decline indicates challenges in market penetration and product adoption, impacting long-term financial health.

Persistent Losses

Ongoing losses reflect operational inefficiencies and high costs, necessitating improved cost management and revenue generation strategies.

Cash Flow Challenges

Negative cash flow indicates difficulties in sustaining operations and funding growth initiatives, potentially limiting strategic opportunities.

Bicycle Therapeutics Business Overview & Revenue Model

Company Description

Bicycle Therapeutics (BCYC) is a biotechnology company focused on developing a new class of medicines known as bicyclic peptide therapeutics. Leveraging its proprietary bicyclic peptide platform, the company aims to create innovative treatments primarily in the fields of oncology and other serious diseases. Bicycle Therapeutics is dedicated to addressing unmet medical needs by harnessing the unique properties of bicyclic peptides, which offer advantages such as enhanced stability, solubility, and targeted delivery compared to traditional therapeutic modalities.

How the Company Makes Money

Bicycle Therapeutics generates revenue through a combination of partnerships, collaborations, and licensing agreements with pharmaceutical companies for the development and commercialization of its therapeutics. The company may receive upfront payments, milestone payments based on the achievement of specific development or regulatory milestones, and royalties on future sales of approved products. Additionally, BCYC may engage in research collaborations that provide funding and support for its drug development programs, further contributing to its revenue stream.

Bicycle Therapeutics Financial Statement Overview

Summary

Bicycle Therapeutics faces significant financial challenges with declining revenues and persistent losses. Despite a low leverage position, negative returns on equity and cash flow difficulties highlight operational inefficiencies. Improvement in revenue generation and cost management is needed to enhance financial stability.

Income Statement

Bicycle Therapeutics shows declining revenue with a negative growth rate of -25.07% in the TTM, indicating significant challenges in revenue generation. The company has consistently negative profit margins, with a TTM net profit margin of -12.57%, reflecting ongoing losses. The EBIT and EBITDA margins are also deeply negative, suggesting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.011 in the TTM, indicating minimal leverage and a conservative capital structure. However, the return on equity is negative at -31.96%, highlighting poor returns for shareholders due to persistent losses. The equity ratio is relatively stable, suggesting a solid asset base funded by equity.

Cash Flow

Bicycle Therapeutics has a negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth at 15.43% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally better than net income, but still negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.34M	35.27M	26.98M	14.46M	11.70M	10.39M
Gross Profit	-167.77M	-137.69M	-129.52M	-67.15M	-33.18M	-22.76M
EBITDA	-270.70M	-164.89M	-183.40M	-112.96M	-64.08M	-50.68M
Net Income	-250.66M	-169.03M	-180.66M	-112.72M	-66.82M	-51.01M
Balance Sheet
Total Assets	763.95M	956.87M	595.34M	410.61M	479.79M	161.15M
Cash, Cash Equivalents and Short-Term Investments	648.33M	879.52M	526.42M	339.15M	438.68M	135.99M
Total Debt	981.00K	9.49M	44.96M	44.33M	44.34M	15.78M
Total Liabilities	145.47M	163.81M	224.41M	139.83M	133.54M	65.69M
Stockholders Equity	618.48M	793.06M	370.93M	270.78M	346.25M	95.46M
Cash Flow
Free Cash Flow	-241.87M	-165.96M	-63.56M	-105.10M	-16.82M	-18.99M
Operating Cash Flow	-239.69M	-164.72M	-60.63M	-86.11M	-14.79M	-17.79M
Investing Cash Flow	-2.14M	-1.24M	-2.93M	-18.99M	-2.03M	-1.20M
Financing Cash Flow	87.00K	519.75M	250.03M	6.69M	320.73M	62.84M

Bicycle Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCYC, the sentiment is Negative. The current price of 6.56 is below the 20-day moving average (MA) of 7.57, below the 50-day MA of 7.58, and below the 200-day MA of 8.45, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 39.08 is Neutral, neither overbought nor oversold. The STOCH value of 19.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCYC.

Bicycle Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	56 Neutral	$453.75M	―	-34.17%	―	102.77%	-17.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCAX	48 Neutral	$816.80M	―	-26.64%	―	―	―
NBTX	48 Neutral	$1.03B	―	―	―	―	―
BCYC	41 Neutral	$454.65M	―	-34.63%	―	-23.43%	-9.84%
OPT	39 Underperform	$477.76M	-3.01	―	―	-80.09%	60.14%
KOD	35 Underperform	$1.07B	―	-140.33%	―	―	-0.69%

Bicycle Therapeutics Corporate Events

Bicycle Therapeutics Reports Q3 2025 Financial Results

Bicycle Therapeutics is a clinical-stage pharmaceutical company based in the United Kingdom, specializing in the development of a novel class of medicines known as Bicycle molecules, primarily targeting oncology indications with high unmet medical needs. The company is known for its unique therapeutic modality that combines the pharmacology of biologics with the manufacturing and pharmacokinetic properties of small molecules.

Bicycle Therapeutics Expands Board with New Appointments

On September 8, 2025, Bicycle Therapeutics announced the expansion of its Board of Directors from eight to ten members, appointing Roger Dansey, M.D., and Hervé Hoppenot as new directors. Both appointees bring extensive expertise in oncology research, drug development, and commercialization, which is expected to enhance the company’s strategic initiatives in developing next-generation targeted therapies. The appointments are seen as a strategic move to strengthen the company’s leadership as it progresses with its pipeline and anticipates upcoming milestones.

The most recent analyst rating on (BCYC) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.

Bicycle Therapeutics Reports Q2 2025 Financial Results

Bicycle Therapeutics is a clinical-stage pharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules, which are designed to address diseases underserved by existing therapeutics. The company operates in the biotechnology sector and is known for its proprietary bicyclic peptide technology.

Bicycle Therapeutics Appoints Charles Swanton to Board

On August 6, 2025, Bicycle Therapeutics announced the appointment of Charles Swanton, M.D., Ph.D., to its Board of Directors and Scientific Committee, effective August 12, 2025. This appointment is part of the company’s efforts to strengthen its clinical leadership and scientific advisory capabilities. Additionally, Bicycle Therapeutics reported its second-quarter 2025 financial results, highlighting significant progress in its research and development pipeline, including ongoing trials for zelenectide pevedotin in various cancers. The company also announced a strategic cost realignment, primarily through workforce reduction, to extend its financial runway into 2028, while continuing to focus on disciplined capital allocation and operational flexibility.

The most recent analyst rating on (BCYC) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.